SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Amyloid beta-peptide (Abeta) deposition in cerebral vessels contributes to cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD). Here, we report that in AD patients and two mouse models of AD, overexpression of serum response factor (SRF) and myocardin (MYOCD) in cerebral vascular smooth muscle cells (VSMCs) generates an Abeta non-clearing VSMC phenotype through transactivation of sterol regulatory element binding protein-2, which downregulates low density lipoprotein receptor-related protein-1, a key Abeta clearance receptor. Hypoxia stimulated SRF/MYOCD expression in human cerebral VSMCs and in animal models of AD. We suggest that SRF and MYOCD function as a transcriptional switch, controlling Abeta cerebrovascular clearance and progression of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the low-density lipoprotein receptor–related protein-1, a critical Aβ brain clearance receptor, is downregulated in cerebral blood vessels of patients with Alzheimer disease, leading to accumulation of amyloid around blood vessels and worsening of vascular dysfunction.129”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“In particular, suppression of LRP1 in vascular smooth muscle cells due to upregulation of serum response factor and myocardin, is a key factor in the clearance impairment (Bell et al., 2009).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Bell et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“dtd" [ ]> Dementia in Alzheimer's disease (AD) is associated with neurovascular dysfunctio”
Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022066 · Cited by 2,313
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213 · cited 1×
“dtd" [ ]> Dementia in Alzheimer's disease (AD) is associated with neurovascular dysfunctio”
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“The low-density lipoprotein receptor-related protein 1 (LRP) is a major Aβ clearance receptor at the BB”
BackgroundWolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398 · cited 1×
“Previous studies have shown that people chronically treated with cholesterol-lowering drugs, such as statins, are less prone to develop A”
BackgroundAdult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Wang, D.-Z., Chang, P. S., Wang, Z., Sutherland, L., Richardson, J. A., Small, E., Krieg, P. A., & Olson, E. N. (2001) · Cell · doi:10.1016/s0092-8674(01)00404-4 · Cited by 898
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Self-citationCerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study
Ruitenberg, A., den Heijer, T., Bakker, S. L. M., van Swieten, J. C., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20493 · Cited by 733 · cited 1×
“Brains of AD patients are chronically hypoperfused and exposed to hypoxi”
BackgroundAlzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680 · cited 1×
“, the prevalence of which is greater than 80% in AD individuals and 10–40% in the elderly population without A”
BackgroundBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Self-citationSerum response factor: toggling between disparate programs of gene expression
Miano, J. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00110-x · Cited by 586
Self-citationClearing the brain's amyloid cobwebs
Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541 · cited 1×
“Recent work has suggested that Aβ accumulates in the wall of cerebral vessels and in brains of AD individuals because of its impaired clearance from the brain and/or imbalances between its production and clearanc”
BackgroundRAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519 · cited 1×
“SRF and MYOCD downregulate LRP in cerebral VSMC As LRP, a key Aβ clearance receptor, is downregulated in AD cerebral vessels in situ”
BackgroundPipes, G. C. T., Creemers, E. E., & Olson, E. N. (2006) · Genes & Development · doi:10.1101/gad.1428006 · Cited by 475
Clearance of Alzheimer's Aβ Peptide
Tanzi, R. E., Moir, R. D., & Wagner, S. L. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.024 · Cited by 411
Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide
Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A. M., Berezovska, O., Hyman, B. T., Chang, T. Y., Tanzi, R. E., & Kovacs, D. M. (2001) · Nature Cell Biology · doi:10.1038/ncb1001-905 · Cited by 392
Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392 · cited 1×
“We reported that statins can increase LRP expression in vascular cells in the presence of A&beta”
BackgroundSelf-citationClearance of amyloid-β by circulating lipoprotein receptors
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1635 · Cited by 373 · cited 1×
“In addition, soluble LRP in plasma provides a key endogenous peripheral 'sink' for Aβ in humans, which is impaired in A”
BackgroundSelf-citationDavis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · cited 1×
“In mouse models of familial AD expressing the Swedish mutation in the Aβ-precursor protein ( APPsw ± ), or harbouring the Dutch and Iowa vasculotropic APP mutations, the dense plaques may develop initially on blood vessels or as classical CA”
BackgroundSelf-citationThe serum response factor coactivator myocardin is required for vascular smooth muscle development
Li, S., Wang, D.-Z., Wang, Z., Richardson, J. A., & Olson, E. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1233635100 · Cited by 343 · cited 1×
“As genetic inactivation of Myocd or Srf is embryonic letha”
BackgroundAtorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results
Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., & Ziolwolski, C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.753 · Cited by 319 · cited 1×
“Previous studies have shown that people chronically treated with cholesterol-lowering drugs, such as statins, are less prone to develop A”
BackgroundAmyloid Angiopathy–Related Vascular Cognitive Impairment
Greenberg, S. M., Gurol, M. E., Rosand, J., & Smith, E. E. (2004) · Stroke · doi:10.1161/01.str.0000143224.36527.44 · Cited by 298 · cited 1×
“Aβ deposition in VSMCs of small cerebral arteries contributes to cerebral amyloid angiopathy (CAA”
BackgroundRole of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Self-citationPettersen, J. A., Sathiyamoorthy, G., Gao, F.-Q., Szilagyi, G., Nadkarni, N. K., St George-Hyslop, P., Rogaeva, E., & Black, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.6.790 · Cited by 264 · cited 1×
“Microbleeds in the brain occur in 80% of CAA cases and in 30% of AD patients with CA”
BackgroundRestricted inactivation of serum response factor to the cardiovascular system
Miano, J. M., Ramanan, N., Georger, M. A., de Mesy Bentley, K. L., Emerson, R. L., Balza, R. O., Xiao, Q., Weiler, H., Ginty, D. D., & Misra, R. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406041101 · Cited by 256 · cited 1×
“and that its expression is sharply reduced in Srf -null mic”
BackgroundSelf-citationEtkin, A., Alarcón, J. M., Weisberg, S. P., Touzani, K., Huang, Y. Y., Nordheim, A., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.013 · Cited by 218
Chow, N., Bell, R. D., Deane, R., Streb, J. W., Chen, J., Brooks, A., Van Nostrand, W., Miano, J. M., & Zlokovic, B. V. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608251104 · Cited by 209 · cited 1×
“, two interacting transcription factors that control VSMC differentiation, are overexpressed in AD and produce a hypercontractile VSMC phenotype in small cerebral arteries through directed expression of SRF–MYOCD-regulated contractile gene”
BackgroundSelf-citationParlakian, A., Tuil, D., Hamard, G., Tavernier, G., Hentzen, D., Concordet, J.-P., Paulin, D., Li, Z., & Daegelen, D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5281-5289.2004 · Cited by 199 · cited 1×
“and that its expression is sharply reduced in Srf -null mic”
BackgroundSato, R., Yang, J., Wang, X., Evans, M. J., Ho, Y. K., Goldstein, J. L., & Brown, M. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32550-4 · Cited by 197
Clearance of amyloid β-peptide from brain: transport or metabolism?
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186
Kumar-Singh, S., Pirici, D., McGowan, E., Serneels, S., Ceuterick, C., Hardy, J., Duff, K., Dickson, D., & Van Broeckhoven, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62995-1 · Cited by 184 · cited 1×
“In mouse models of familial AD expressing the Swedish mutation in the Aβ-precursor protein ( APPsw ± ), or harbouring the Dutch and Iowa vasculotropic APP mutations, the dense plaques may develop initially on blood vessels or as classical CA”
BackgroundCardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor
Zhang, X., Azhar, G., Chai, J., Sheridan, P., Nagano, K., Brown, T., Yang, J., Khrapko, K., Borras, A. M., Lawitts, J., et al. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.4.h1782 · Cited by 146
Neuronal migration in the murine rostral migratory stream requires serum response factor
Alberti, S., Krause, S. M., Kretz, O., Philippar, U., Lemberger, T., Casanova, E., Wiebel, F. F., Schwarz, H., Frotscher, M., Schütz, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501191102 · Cited by 145
Niu, Z., Yu, W., Zhang, S. X., Barron, M., Belaguli, N. S., Schneider, M. D., Parmacek, M. S., Nordheim, A., & Schwartz, R. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501372200 · Cited by 145 · cited 1×
“and that its expression is sharply reduced in Srf -null mic”
BackgroundMyocardin is a bifunctional switch for smooth versus skeletal muscle differentiation
Long, X., Creemers, E. E., Wang, D.-Z., Olson, E. N., & Miano, J. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708253104 · Cited by 96 · cited 1×
“MYOCD acts as a potent repressor of MyoD-mediated skeletal muscle cell differentiation in an SRF-CArG element independent manne”
BackgroundSelf-citationZhu, P., Huang, L., Ge, X., Yan, F., Wu, R., & Ao, Q. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2006.00503.x · Cited by 96 · cited 1×
“This is consistent with earlier reports suggesting that hypoxia increases the levels of MYOCD mRNA in cultured VSM”
ResultYang, J., Brown, M. S., Ho, Y. K., & Goldstein, J. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.20.12152 · Cited by 95
Nazer, B., Hong, S., & Selkoe, D. J. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.005 · Cited by 90
Environmental Enrichment Counteracts Alzheimer’s Neurovascular Dysfunction in TgCRND8 Mice
Herring, A., Yasin, H., Ambrée, O., Sachser, N., Paulus, W., & Keyvani, K. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00094.x · Cited by 88 · cited 1×
“Impaired LRP-mediated clearance of Aβ in VSMCs in AD and AD models is consistent with reports demonstrating diminished LRP-mediated Aβ clearance at the BBB in AD and AD model”
ResultCoaxing the LDL Receptor Family into the Fold
Herz, J., & Marschang, P. (2003) · Cell · doi:10.1016/s0092-8674(03)00073-4 · Cited by 87 · cited 1×
“The role of LRP as an Aβ clearance receptor on VSMC, as shown in the present study, is consistent with its reported role as an endocytic cargo recepto”
ResultLLORENTECORTES, V, ROYO, T., OTEROVINAS, M., BERROZPE, M., & BADIMON, L. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.02.020 · Cited by 70
Llorente‐Cortés, V., Costales, P., Bernués, J., Camino-López, S., & Badimón, L. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.04.008 · Cited by 67
Parsons, R. B., Price, G. C., Farrant, J. K., Subramaniam, D., Adeagbo-Sheikh, J., & Austen, B. M. (2006) · Biochemical Journal · doi:10.1042/bj20060655 · Cited by 50
LRP-Mediated Clearance of Aβ is Inhibited by KPI-Containing Isoforms of APP
Moir, R., & Tanzi, R. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585918 · Cited by 42
Role of A β Transport and Clearance in the Pathogenesis and Treatment of Alzheimer’s Disease
Holtzman, D. M., & Zloković, B. V. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_11 · Cited by 16
Evidence of basolateral water permeability regulation in amphibian urinary bladder
Candia, O. A., Mia, A. J., & Yorio, T. (1997) · Biology of the Cell · doi:10.1111/j.1768-322x.1997.tb01030.x · Cited by 13
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
(2007) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2007.00523.x · Cited by 2
(1997) · PubMed
Research works printed but not linked: 1
- Holtzman, D. M. et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47, 739–747 (2000). · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Self-citationA molecular atlas of cell types and zonation in the brain vasculature
Vanlandewijck, M., He, L., Mäe, M. A., Andrae, J., Ando, K., Del Gaudio, F., Nahar, K., Lebouvier, T., Laviña, B., Gouveia, L., et al. (2018) · Nature · doi:10.1038/nature25739 · Cited by 1,892
Metadata
- Authors
- Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., Miano, J. M., & Zlokovic, B. V.
- Affiliations
- University of Rochester Medicine (US)
- Venue
- Nature Cell Biology
- Published
- 2008-12-21
- Volume
- 11
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC2654279
- OpenAlex
- W2094117787
- Cited by
- 261
- References
- 52
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 10 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 19 · 2016: 12 · 2015: 19 · 2014: 20 · 2013: 17 · 2012: 29
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Chinese Academy of Agricultural Sciences
- National Institutes of Health
- National Institute on Aging (R37AG023084, R42AG026950, 1R43 AG02400)
- National Heart, Lung, and Blood Institute (R01HL132574, HL 62572, R01HL062572, R01HL091168)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R01NS034467, R37NS34467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- serum response factor, myocardin, LRP1, amyloid-beta clearance, cerebral amyloid angiopathy, Alzheimer's disease, SREBP2, cerebral hypoxia, transcriptional regulation
- MeSH terms
- Myocardin, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Blood-Brain Barrier, Cells, Cultured, Cerebral Arteries, Disease Models, Animal, Female, Humans, Male, Mice, Transgenic, Muscle, Smooth, Vascular, Nuclear Proteins, Transcriptional Activation, Trans-Activators, Down-Regulation, Amyloid beta-Peptides, Serum Response Factor, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Sterol Regulatory Element Binding Protein 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.